Small Cap Gainers: ENDP, CYTK, PLXP
3:17 pm Tuesday, July 20th, 2021
Endo International PLC (NASDAQ: ENDP) gains on above 5x average volume. Among recent items, local press in Tennessee reported last night that co has made a settlement offer to counties involved in its opioid trial in Tennessee. Elsewhere in the pharmaceuticals space, McKesson (MCK), AmerisourceBergen (ABC), and Cardinal Health (CAH) today announced that they have agreed to pay up to $1.179 bln in a settlement with the State of New York and participating subdivisions to resolve opioid-related claims. The stock is up by 29.50% to $4.35
Cytokinetics, Inc. (NASDAQ: CYTK) stock gained 8% to $29.25 Announced a public offering of $200.0 mln of its common shares. The stock sees continued strength following co’s announcement of top-line results from its REDWOOD-HCM trial yesterday. Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.
PLx Pharma Inc (NASDAQ: PLXP) moved up 21% to $20.50 after the company announced that three stock-keeping units of its lead product, VAZALORE, will be available in over 8,000 Walgreens (WBA) stores nationwide in August. The announcement follows co’s update last week that it will launch VAZALORE in over 4,500 Walmart (WMT) stores next month. At new multi-year highs.
